Back to Newsroom

ProMIS Neurosciences to Present Preclinical Data from Alzheimer’s Disease Program at AAIC 2017

TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 5, 2017– ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the Company will present preclinical data for its lead product candidate, PMN310, at the Alzheimer’s Association International Conference (AAIC) to be held in London on July 16-20.